Regulus Therapeutics
RGLS

$1.74

1.75%

Market Cap: $114M

About: Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Employees: 31

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

176% more call options, than puts

Call options by funds: $329K | Put options by funds: $119K

40% more funds holding

Funds holding: 45 [Q1] → 63 (+18) [Q2]

14.07% more ownership

Funds ownership: 79.6% [Q1] → 93.68% (+14.07%) [Q2]

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

26% less capital invested

Capital invested by funds: $147M [Q1] → $109M (-$37.9M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

302%

upside

Avg. target

$13

647%

upside

High target

$28

1,509%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Andreas Argyrides 76% 1-year accuracy 26 / 34 met price target	302%upside $7	Outperform Reiterated	14 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	475%upside $10	Buy Reiterated	9 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	475%upside $10	Buy Reiterated	16 Jul 2024
Canaccord Genuity Whitney Ijem 55% 1-year accuracy 12 / 22 met price target	1,509%upside $28	Buy Maintained	25 Jun 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	475%upside $10	Buy Maintained	25 Jun 2024

See Analyst Rankings

Financial journalist opinion

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ET H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m.

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO , Aug. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13 th at 8:30 a.m. ET. A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

SAN DIEGO , July 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: H.C. Wainwright Third Annual Kidney Virtual Conference: Fireside chat on Monday, July 15, 2024, at 10:30 a.m.

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO , June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD.

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization.

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024.

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 expected in mid-2024 Ended first quarter 2024 with cash, cash equivalents, and investments of $107.7 million; Cash runway into H1 2026 SAN DIEGO , May 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Our work in ADPKD continues to progress and most recently we announced the initiation of our fourth, and final, cohort in the Phase 1b MAD study of RGLS8429," said Jay Hagan, CEO of Regulus.

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains.

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months.

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

See News Rankings